Results from METRICs Study Informs Expansion of StageZero's New Care Oncology Protocol
Launch of New Protocol will now make the connection between patients' metabolic health and cancer outcomes using advanced biomarker testing and interactive digital health platform to actively track patient progress.
Metabolically targeted drugs show promise as adjunctive therapy to make cancer cells more sensitive to chemotherapy, radiation and other standard of care treatments. By coupling the COC Protocol with specific blood biomarker data, this will enable our clinical team to objectively assess the degree of metabolic control which may be being exercised by the COC Protocol and to further refine the dosing and treatment over time.
"By adding biomarker testing, a proprietary algorithm and new digital health platform to track patient progress while on the protocol, it will enable us to better evaluate the connection between metabolic status and cancer outcomes. As we connect outcomes to improved metabolic and inflammatory health, it could change the way cancer is treated," said James Howard-Tripp, Chairman and CEO of StageZero Life Sciences. "This new protocol is intended to benefit patients, but will also serve as the foundation for METRICS II, a novel approach to generate additional clinical data of sufficient quality to support changes in clinical practice," he added.